This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Severe Congenital Neutropenia
Information about Severe Congenital Neutropenia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Severe Congenital Neutropenia
Most recent studies have shown that Severe Congenital Neutropenia shares some biological mechanisms with agranulocytosis, anemia, bacterial-infections, cell-transformation-neoplastic, cyclic-neutropenia, dysmyelopoietic-syndromes, growth-arrest, hematological-disease, immunologic-deficiency-syndromes, infective-disorder, leukemia, leukemia-myelocytic-acute, malignant-neoplasms, malignant-paraganglionic-neoplasm, myeloid-leukemia, neutropenia-chronic, pancytopenia, shwachman-syndrome, systemic-infection.
Among the many pathways, these few ones have gauged particular interests from scientists studying Severe Congenital Neutropenia, and have been seen in publications frequently: Bone Resorption, Cell Cycle, Cell Death, Cell Development, Cell Differentiation, Cell Maturation, Cell Migration, Cell Proliferation, Chemotaxis, Energy Homeostasis, Glycosylation, Hypersensitivity, Localization, Neutrophil Differentiation, Pathogenesis, Phagocytosis, Programmed Cell Death, Proteolysis, Transport, Wound Healing
Quite a number of genes have been found to play important roles in Severe Congenital Neutropenia, such as ASXL1, CD34, CSF2, CSF3, CSF3R, ELANE, G6PC, G6PC3, GFI1, HAX1, IL3, KITLG, LEF1, PAFAH1B1, SF3B1, WAS, YWHAE. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.